A Nested Case-control Study to Determine the Relative Risk of and Risk Factors for Interstitial Lung Disease in a Cohort of NSCLC Patients Treated With and Without Gefitinib.

Trial Profile

A Nested Case-control Study to Determine the Relative Risk of and Risk Factors for Interstitial Lung Disease in a Cohort of NSCLC Patients Treated With and Without Gefitinib.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Dec 2016

At a glance

  • Drugs Gefitinib (Primary) ; Antineoplastics
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Dec 2007 Status changed from in progress to completed.
    • 08 Jun 2007 Status change from recruting to in progress
    • 24 Mar 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top